Patents by Inventor Robert A. Mook, Jr.

Robert A. Mook, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10905665
    Abstract: Described are methods of treating a disease associated with dysregulation of the Wnt/Frizzled signaling pathway. The methods include identifying subjects in need of therapy, administering inhibitors of the Wnt/Frizzled signaling pathway, pharmaceutical compositions including the inhibitors, and methods of using the compounds and compositions for treating cancer, bacterial and viral infection, lupus, type II diabetes, nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD) in a subject.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: February 2, 2021
    Assignee: Duke University
    Inventors: Wei Chen, Robert A. Mook, Jr., Jiangbo Wang, Xiu-rong Ren, Minyong Chen, Lawrence S. Barak, Herbert Kim Lyerly, David Needham
  • Patent number: 10562864
    Abstract: Compounds and pharmaceutical compositions that down-regulate immune checkpoints such as PD-1, PD-L1 and CTLA-4 are provided. Also provided are methods of treating a disease by down-regulating immune checkpoints such as PD-1, PD-L1 and CTLA-4. The methods are useful for treating cancer and viral infection in a subject.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: February 18, 2020
    Assignee: Duke University
    Inventors: Wei Chen, Herbert Kim Lyerly, Xiu-rong Ren, Jiangbo Wang, Hongtao Guo, Amy Hobeika, Robert A. Mook, Jr.
  • Publication number: 20200038350
    Abstract: Described are methods of treating a disease associated with dysregulation of the Wnt/Frizzled signaling pathway. The methods include identifying subjects in need of therapy, administering inhibitors of the Wnt/Frizzled signaling pathway, pharmaceutical compositions including the inhibitors, and methods of using the compounds and compositions for treating cancer, bacterial and viral infection, lupus, type II diabetes, nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD) in a subject.
    Type: Application
    Filed: June 24, 2016
    Publication date: February 6, 2020
    Inventors: Wei Chen, Robert A. Mook, JR., Jiangbo Wang, Xiu-rong Ren, Minyong Chen, Lawrence S. Barak, Herbert Kim Lyerly, David Needham
  • Publication number: 20190070154
    Abstract: Described are methods of treating a disease associated with dysregulation of the Wnt/Frizzled signaling pathway. The methods include identifying subjects in need of therapy, administering inhibitors of the Wnt/Frizzled signaling pathway, pharmaceutical compositions including the inhibitors, and methods of using the compounds and compositions for treating cancer, bacterial Sand viral infection, lupus, type II diabetes, nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD) in a subject.
    Type: Application
    Filed: June 24, 2016
    Publication date: March 7, 2019
    Inventors: Wei Chen, Robert A. Mook, Jr., Jiangbo Wang, Xiu-rong Ren, Minyong Chen, Lawrence S. Barak, Herbert Kim Lyerly
  • Publication number: 20180340005
    Abstract: The present disclosure provides modified neuroactive steroids. The modified neuroactive steroids may comprise, consist of or consist essentially of a therapeutic agent and/or a modifying moiety. The modified neuroactive steroid can have modified characteristics as compared to native neuroactive steroids that do not include a modifying moiety and/or therapeutic agent. The modified neuroactive steroid may be, for example, modified pregnenolone, pregnenolone metabolites, allopregnanolone, and/or allopregnanolone metabolites. The modified neuroactive steroids can be used to treat, prevent and/or ameliorating a phenotypic state of interest in a subject.
    Type: Application
    Filed: December 21, 2017
    Publication date: November 29, 2018
    Inventors: Christine Marx, Robert Mook, JR.
  • Patent number: 9512106
    Abstract: Compounds of general Formulas (I), (IA), (IB) are described, along with compositions containing the same and methods of use thereof, inhibiting the hedgehog pathway in a cell or inhibiting unwanted proliferation of a cell.
    Type: Grant
    Filed: September 16, 2013
    Date of Patent: December 6, 2016
    Assignee: Duke University
    Inventors: Wei Chen, Jiangbo Wang, Robert A. Mook, Jr., Lawrence S. Barak, H. Kim Lyerly, Anthony Angelo Ribeiro
  • Publication number: 20150166509
    Abstract: Compounds of general Formulas (I), (IA), (IB) are described, along with compositions containing the same and methods of use thereof, inhibiting the hedgehog pathway in a cell or inhibiting unwanted proliferation of a cell.
    Type: Application
    Filed: September 16, 2013
    Publication date: June 18, 2015
    Inventors: Wei Chen, Jiangbo Wang, Robert A. Mook, JR., Lawrence S. Barak, H. Kim Lyerly, Anthony Angelo Ribeiro
  • Publication number: 20070010668
    Abstract: The present invention provides compounds of formula (I): wherein all variables are as defined herein, pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.
    Type: Application
    Filed: February 11, 2004
    Publication date: January 11, 2007
    Inventors: Ronda Davis-Ward, Robert Mook Jr., Michael Neeb, James Salovich
  • Patent number: 5846976
    Abstract: The present invention relates to the compound of formula (I), ##STR1## also known as 17.beta.-N-(2,5-bis(Trifluoromethyl))phenylcarbamoyl-4-aza-5.alpha.-andros t-1-en-3-one, solvates thereof, its preparation, intermediates used in its preparation, pharmaceutical formulations thereof and its use in the treatment of androgen responsive and mediated diseases.
    Type: Grant
    Filed: August 22, 1996
    Date of Patent: December 8, 1998
    Assignee: Glaxo Wellcome Inc.
    Inventors: Kenneth William Batchelor, Stephen Vernon Frye, George F. Dorsey, Jr., Robert A. Mook, Jr.
  • Patent number: 5705693
    Abstract: The present invention is directed to new cationic lipids and intermediates in their synthesis that are useful for transfecting nucleic acids or peptides into prokaryotic or eukaryotic cells. The lipids comprise one or two substituted arginine, lysine or ornithine residues, or derivatives thereof, linked to a lipophilic moiety. The lipids form a complex when mixed with polyanions such as nucleic acids or peptides. The complexes permit efficient transfer of polyanions into cells, usually without significant toxicity to the cells.
    Type: Grant
    Filed: July 7, 1995
    Date of Patent: January 6, 1998
    Assignee: Gilead Sciences, Inc.
    Inventors: Randolph B. DePrince, Kevin L. Facchine, George S. Lewis, Jason G. Lewis, Kuei-Ying Lin, Mark D. Matteucci, Robert A. Mook, Jr., Richard W. Wagner
  • Patent number: 5565467
    Abstract: The present invention relates to the compound of formula (I), ##STR1## also known as 17.beta.-N-(2,5-bis(Trifluoromethyl))phenylcarbamoyl-4-aza-5.alpha.-andros t-1-en-3-one, solvates thereof, its preparation, intermediates used in its preparation, pharmaceutical formulations thereof and its use in the treatment of androgen responsive and mediated diseases.
    Type: Grant
    Filed: March 16, 1995
    Date of Patent: October 15, 1996
    Assignee: Glaxo Wellcome Inc.
    Inventors: Kenneth W. Batchelor, Stephen V. Frye, George F. Dorsey, Jr., Robert A. Mook, Jr.
  • Patent number: 5241069
    Abstract: This invention relates to the new process for preparing the 1R-cis isomer of carbovir, (1R-cis)-amino-1,9-dihydro-9-[4-(hydroxymethyl)-2-cyclopenten-1-yl]-6H-pur in-6-one, an antiviral agent and intermediates of the formula (Vlb) use in that process ##STR1## wherein X is chloro, bromo or iodo and R is (C.sub.1-6) alkyl.
    Type: Grant
    Filed: November 6, 1991
    Date of Patent: August 31, 1993
    Assignees: Glaxo Inc., Univeristy of Minnesoota
    Inventors: Robert Vince, Mark L. Peterson, John W. Lackey, Robert A. Mook, Jr., John J. Partridge
  • Patent number: 5126452
    Abstract: This invention relates to new process for preparing certain optically active purine substituted cyclopentene derivatives and novel intermediates used in this process. In particular, the invention concerns the synthesis of the 1R-cis isomer of carbovir, (1R-cis)-amino-1,9-dihydro-9-[4-(hydroxymethyl)-2-cyclopenten-1-yl]-6H-pur in-6-one, an antiviral agent, and certain intermediates.
    Type: Grant
    Filed: April 6, 1990
    Date of Patent: June 30, 1992
    Assignee: Glaxo Inc.
    Inventors: Robert Vince, Mark L. Peterson, John W. Lackey, Robert A. Mook, Jr., John J. Partridge
  • Patent number: 5057630
    Abstract: This invention relates to a new process for preparing certain optically active purine substituted cyclopentene derivatives including the antiviral agent, carbovir, and novel intermediates used in this process. In particular, this invention concerns a synthesis of (1R-cis)-4-hydroxymethyl-2-cyclopenten-1-ol, an intermediate in this process.
    Type: Grant
    Filed: April 6, 1990
    Date of Patent: October 15, 1991
    Assignee: Glaxo Inc.
    Inventors: John W. Lackey, Robert A. Mook, Jr., John J. Partridge